VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASCO 2015 | Results for the follow-up of the RESPONSE study

Jean-Jacques Kiladjian • 2 Jun 2015
ASCO 2015
Myeloproliferative Neoplasms Ruxolitinib

Dr Jean-Jacques Kiladjian discusses the results of the follow up to the RESPONSE study of ruxolitinib versus standard therapy for the treatment of patients with polycythemia vera.

More from Jean-Jacques Kiladjian

1:45
Design and results of pacritinib for myelofibrosis trial (PERSIST-1)
Jean-Jacques Kiladjian • 2 Jun 2015
1:45
What's new in myeloproliferative neoplasms?
Jean-Jacques Kiladjian • 9 Jun 2016
1:43
Factors predicting durable remission after IFN therapy discontinuation in MPN patients
Jean-Jacques Kiladjian • 11 Dec 2020
2:18
Molecular profiling and risk classification of patients with MPNs and splanchnic vein thromboses
Jean-Jacques Kiladjian • 26 Aug 2020

Related Videos

1:42
Early allogeneic transplantation for myelofibrosis patients responding to ruxolitinib
Juan Carlos Hernández-Boluda • 20 Oct 2021
1:56
Outcomes of older myelofibrosis patients who receive allogeneic transplantation
Juan Carlos Hernández-Boluda • 20 Oct 2021
2:27
Improving our understanding of MDS for better disease management
Sandra Kurtin • 22 Sep 2021
5:14
DNA and RNA assay for myeloid malignancies
Michael Rauh • 22 Sep 2021
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals